Scoliosis
Drug research and approvals for scoliosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 108 studies of scoliosis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 2 drug trials for it since 2013.
- Recruiting worldwide: 108
- Trials authorized in Canada: 2
- FDA orphan approvals: 0
- EU medicines: 0
- Turkish Adaptation and Validation of the Scoliosis Misconception Scale in Adolescents With Idiopathic ScoliosisNCT07909174 · Not reported · Kahramanmaras Sutcu Imam University · starts Oct 21, 2026
- Hypnosis for Pain and Nausea Reduction in Scoliosis Surgery: An Interventional StudyNCT07854951 · Not applicable · St. Olavs Hospital · starts Nov 25, 2025
- Supervised vs. Home Schroth Exercise in AISNCT07779070 · Not applicable · Bitlis Eren University · starts Aug 31, 2026
- Sleep Quality in Adolescents With Idiopathic ScoliosisNCT07767591 · Not reported · Bezmialem Vakif University · starts Aug 7, 2026
- Effectiveness of a Horse Riding Simulator in Adolescents With Idiopathic ScoliosisNCT07758712 · Not applicable · Bezmialem Vakif University · starts Aug 5, 2026
- Quality of Life, Psychosocial Burden, and Structural-functional Status in Adults With Spinal Deformity.NCT07749534 · Not applicable · Universitaire Ziekenhuizen KU Leuven · starts Aug 28, 2026
- Management of Early Onset Scoliosis by Active Apex Correction TechniqueNCT07727408 · Not applicable · Al-Azhar University · starts Nov 25, 2023
- Evaluation of the Effect of Reiki on Pain After Lumbar SurgeryNCT07722117 · Not applicable · Clinique Bizet · starts Sep 10, 2025
- Schroth and Pilates for Adolescent Idiopathic ScoliosisNCT07702812 · Not applicable · Ankara Yildirim Beyazıt University · starts Jul 1, 2026
Phase 3 8
- MorphineMu opioid receptor agonist
- AcetaminophenCyclooxygenase inhibitor
- Tranexamic acidPlasminogen inhibitor
- ClonidineAdrenergic receptor alpha-2 agonist
- MethadoneMu opioid receptor agonist
- LidocaineSodium channel alpha subunit blocker
- GabapentinVoltage-gated calcium channel modulator
- Epoetin betaErythropoietin receptor agonist
Phase 2 6
- FentanylMu opioid receptor agonist
- KetorolacCyclooxygenase inhibitor
- MeperidineMu opioid receptor agonist
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- ClevidipineVoltage-gated L-type calcium channel blocker
- AlfacalcidolVitamin D receptor agonist
Phase 1 or earlier 2
- DexmedetomidineAdrenergic receptor alpha-2 agonist
- PropofolGABA-A receptor; anion channel positive allosteric modulator
How its trials ended
593 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 66 whose ending is known, 30% met their primary endpoint, 3% missed it and 67% stopped early.
- Completed, result not reported26144%
- Ongoing19333%
- Status unknown7312%
- Stopped: other or unclear285%
- Met its primary endpoint203%
- Stopped: enrollment or feasibility61%
- Stopped: lack of efficacy41%
- Stopped: sponsor or business decision41%
- Missed its primary endpoint2<1%
- Stopped: funding2<1%
| Aug 15, 2019 | Perioperative multimodal analgesia including intravenous lidocaine infusion for pain management following idiopathic scoliosis correction surgery in childrenLidocaine | British Columbia Childrens Hospital | Ongoing |
| Feb 9, 2018 | Sensorial and physiological mechanism-based assessments of perioperative painClonidine | Shriners Hospital for Children Canada | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA